Replies to post #229879 on NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

Yes psuedo progression with the right imaging tools to identify freind or foe. Like the military IFF. Cancer is War.

Now that they know what signal to look for, they can drill down and use other contrast to determine what type of cells they are seeing.

.

I can't find the other video right now but there was 1 that showed advanced imaging to detect immune cells.

[survivor1x]

I think you will find this link very interesting.

https://www.pnas.org/content/114/38/10220

We have identified a novel noninvasive imaging combination that could distinguish intracranial immune responses from tumor progression in mice bearing orthotopic gliomas and in patients with glioblastomas.

[GermanCol]

Senti, I don't post too much because English is not my native language (this is my second post on this board and around number 135 in total), but have been an NWBO shareholder for around 3 years and increased my stake this week with ASCO coming this weekend. Wanted to tell you that I have been following you (and some other posters here) for months because I think your posts are great and very informative. Also wanted to ask you a question regarding PFS and pseudoprogression.

You mentioned in a post that in February 2017 management announced they reached the primary endpoint number (248). Do you think that date will be restated as a later date (I guess that is possible if they have clear evidence to change it) with what they have been finding about pseudo progression (that for what I understand was mistaken before as real progression) and announce something like that at ASCO or in the near future?